Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment

Biomaterials

Volumn 33, Issue 2, 2012, Pages 704-712

  Ting, Chien Yu ^a   Fan, Ching Hsiang ^a   Liu, Hao Li ^b   Huang, Chiung Yin ^c   Hsieh, Han Yi ^b   Yen, Tzu Chen ^c   Wei, Kuo Chen ^c   Yeh, Chih Kuang ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Blood brain barrier (BBB); Chemotherapy; Focused ultrasound (FUS); Glioblastoma multiforme (GBM); Microbubble (MB)

Indexed keywords

BLOOD-BRAIN BARRIER; BRAIN TUMOR TREATMENTS; BRAIN TUMORS; CYTOTOXIC EFFECTS; FOCUSED ULTRASOUND; GLIOBLASTOMA MULTIFORME; GLIOBLASTOMA MULTIFORME (GBM); HIGH LOADINGS; LOCAL DRUG DELIVERY; MEDIAN SURVIVAL; MICRO-BUBBLE; MICROBUBBLE (MB); MICROBUBBLES; RAPID DEGRADATION; RETICULOENDOTHELIAL SYSTEMS; TARGET SITES; THERAPEUTIC DOSE; TUMOR PROGRESSIONS;

ANIMALS; BLOOD; CHEMOTHERAPY; CYTOTOXICITY; DRUG DELIVERY; TUMORS; ULTRASONICS;

DRUG DOSAGE;

CARMUSTINE; DRUG CARRIER;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG RELEASE; ENCAPSULATION; FEASIBILITY STUDY; GLIOMA; MALE; MICROBUBBLE; NONHUMAN; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM; TUMOR GROWTH; ULTRASOUND;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD-BRAIN BARRIER; BRAIN; CARMUSTINE; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HALF-LIFE; MAGNETIC RESONANCE IMAGING; MALE; MICROBUBBLES; NUCLEIC ACID CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; ULTRASONIC THERAPY;

ANIMALIA;

EID: 80055109177     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.096     Document Type: Article

References (32)

1. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
2. Arko L., Katsyv I., Park G.E., Luan W.P., Park J.K. Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 2010, 128:1-36.
3. Huse J.T., Holland E.C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010, 10:319-331.
4. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA Cancer J Clin 2006, 56:106-130.
5. Kang C., Yuan X., Zhong Y., Pu P., Guo Y., Albadany A., et al. Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D, L-lactic acid) nanoparticles. Technol Cancer Res Treat 2009, 8:61-70.
6. Chen P.Y., Liu H.L., Hua M.Y., Yang H.W., Huang C.Y., Chu P.C., et al. Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. Neuro Oncol 2010, 12:1050-1060.
7. Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P.C., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, 5:79-88.
8. Marosi C. Chemotherapy for malignant gliomas. Wien Med Wochenschr 2006, 156:346-350.
9. Vogelhuber W., Spruss T., Bernhardt G., Buschauer A., Göpferich A. Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts. Int J Pharm 2002, 238:111-121.
10. Engelhard H.H. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 2000, 53:458-464.
11. Li Y., Ho Duc H.L., Tyler B., Williams T., Tupper M., Langer R., et al. In vivo delivery of BCNU from a MEMS device to a tumor model. J Control Release 2005, 106:138-145.
12. Khil M.S., Kolozsvary A., Apple M., Kim J.H. Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain. Int J Radiat Oncol Biol Phys 2000, 47:511-516.
13. Black K.L., Ningaraj N.S. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control 2004, 11:165-173.
14. Cloughesy T.F., Black K.L. Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol 1995, 26:125-132.
15. Xu X., Chen X., Xu X., Lu T., Wang X., Yang L., et al. BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells. J Control Release 2006, 114:307-316.
16. Vykhodtseva N., McDannold N., Hynynen K. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 2008, 48:279-296.
17. Neuwelt E.A., Barnett P.A., Bigner D.D., Frenkel E.P. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci U S A 1982, 79:4420-4423.
18. Treat L.H., McDannold N., Vykhodtseva N., Zhang Y., Tam K., Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 2007, 121:901-907.
19. Wang F., Cheng Y., Mei J., Song Y., Yang Y.Q., Liu Y., et al. Focused ultrasound microbubble destruction-mediated changes in blood-brain barrier permeability assessed by contrast-enhanced magnetic resonance imaging. J Ultrasound Med 2009, 28:1501-1509.
20. Hynynen K., McDannold N., Sheikov N.A., Jolesz F.A., Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 2005, 24:12-20.
21. Adair J.C., Baldwin N., Kornfeld M., Rosenberg G.A. Radiation-induced blood-brain barrier damage in astrocytoma: relation to elevated gelatinase B and urokinase. J Neurooncol 1999, 44:283-289.
22. Kang J., Wu X., Wang Z., Ran H., Xu C., Wu J., et al. Antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation on VX2 rabbit liver tumors. J Ultrasound Med 2010, 29:61-70.
23. Lee J.S., An T.K., Chae G.S., Jeong J.K., Cho S.H., Lee H.B., et al. Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma. Eur J Pharm Biopharm 2005, 59:169-175.
24. Kim G.Y., Tyler B.M., Tupper M.M., Karp J.M., Langer R.S., Brem H., et al. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. J Control Release 2007, 123:172-178.
25. Wheeler K.T., Levin V.A., Deen D.F. The concept of drug dose for in vitro studies with chemotherapeutic agents. Radiat Res 1978, 76:441-458.
26. Lentacker I., De Smedta S.C., Sanders N.N. Drug loaded microbubble design for ultrasound triggered delivery. Soft Matter 2009, 5:2161-2170.
27. Liu H.L., Hua M.Y., Chen P.Y., Chu P.C., Pan C.H., Yang H.W., et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010, 255:415-425.
28. Tinkov S., Winter G., Coester C., Bekeredjian R. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I-Formulation development and in-vitro characterization. J Control Release 2010, 143:143-150.
29. Yeh C.K., Chen J.J., Li M.L., Luh J.J., Chen J.J. In vivo imaging of blood flow in the mouse Achilles tendon using high-frequency ultrasound. Ultrasonics 2009, 49:226-230.
30. Bouffet E., Tabori U., Huang A., Bartels U. Possibilities of new therapeutic strategies in brain tumors. Cancer Treat Rev 2010, 36:335-341.
31. Daemen T., Regts J., Meesters M., Ten Kate M.T., Bakker-Woudenberg I.A.J.M., Scherphof G.L. Toxicity of doxorubicin entrapped within long-circulating liposomes. J Control Release 1997, 44:1-9.
32. Yuh E.L., Shulman S.G., Mehta S.A., Xie J., Chen L., Frenkel V., et al. Delivery of systemic chemotherapeutic agent to tumors by using focused ultrasound: study in a murine model. Radiology 2005, 234:431-437.